CancerDrs

Brain Cancer clinical trials in Kansas

6 actively recruiting brain cancer trials at 13 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Kansas:
  • Coffeyville Regional Medical Center — Coffeyville, Kansas
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Saint Catherine Hospital — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • HaysMed University of Kansas Health System — Hays, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …

Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Kansas:
  • University of Kansas Medical Center — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any …

Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06465199
Sites in Kansas:
  • Children's Mercy Hospitals and Clinics — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Kansas:
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10